4.0
Dec 21, 2021
Current employee, less than 1 year
Fremont, CA
Recommend
CEO approval
Business Outlook
Pros
Growing company, well compensated, generally good collaboration across regions
Cons
Typical growing pains of a biotech evolving into midsize pharma, nothing particularly negative though